Progyny (PGNY) Financials

$21.26 +0.47 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$20.90 -0.36 (-1.69%)

As of 06:28 PM Eastern

Annual Income Statements for Progyny

This table shows Progyny's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-26	-5.54	-8.57	46	66	30	62	54
Consolidated Net Income / (Loss)	-12	0.66	-8.57	46	66	30	62	54
Net Income / (Loss) Continuing Operations	-12	-5.12	-8.57	46	66	30	62	54
Total Pre-Tax Income	-12	-6.89	-8.56	8.68	32	24	71	83
Total Operating Income	-11	-3.45	9.68	8.35	32	23	62	67
Total Gross Profit	7.40	19	46	70	112	167	239	253
Total Revenue	49	105	230	345	501	787	1,089	1,167
Operating Revenue	49	105	230	345	501	787	1,089	1,167
Total Cost of Revenue	41	86	184	275	388	620	850	914
Operating Cost of Revenue	41	86	184	275	388	620	850	914
Total Operating Expenses	37	23	36	62	80	144	177	186
Selling, General & Admin Expense	14	16	24	47	60	98	117	122
Marketing Expense	4.26	7.29	12	15	20	46	59	64
Total Other Income / (Expense), net	-2.91	-3.44	-18	0.33	0.10	1.10	8.51	16
Other Income / (Expense), net	-2.17	-2.94	-18	0.21	-0.37	1.10	8.51	16
Income Tax Expense	-0.00	-1.78	0.01	-38	-33	-5.92	8.65	29
Basic Earnings per Share	($2.37)	$0.04	($0.41)	$0.54	$0.74	$0.33	$0.65	$0.59
Weighted Average Basic Shares Outstanding	5.68M	5.54M	20.74M	85.72M	89.11M	92.20M	95.02M	91.48M
Diluted Earnings per Share	($2.37)	$0.04	($0.41)	$0.47	$0.66	$0.30	$0.62	$0.57
Weighted Average Diluted Shares Outstanding	5.68M	5.54M	20.74M	99.06M	100.36M	99.96M	100.67M	95.45M
Weighted Average Basic & Diluted Shares Outstanding	5.68M	5.54M	20.74M	87.22M	91.23M	93.38M	96.50M	85.41M

This table shows Progyny's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	13	3.41	18	15	16	13	17	16	10	11
Consolidated Net Income / (Loss)	13	3.41	18	15	16	13	17	16	10	11
Net Income / (Loss) Continuing Operations	13	3.41	18	15	16	13	17	16	10	11
Total Pre-Tax Income	12	4.14	16	17	21	16	23	25	18	18
Total Operating Income	11	3.31	15	15	18	14	19	21	12	16
Total Gross Profit	46	44	59	61	63	57	62	68	59	63
Total Revenue	205	214	258	279	281	270	278	304	287	298
Operating Revenue	205	214	258	279	281	270	278	304	287	298
Total Cost of Revenue	159	170	200	219	218	213	216	236	227	235
Operating Cost of Revenue	159	170	200	219	218	213	216	236	227	235
Total Operating Expenses	35	41	44	45	44	43	44	48	47	48
Selling, General & Admin Expense	24	28	29	30	30	28	28	31	30	32
Marketing Expense	11	13	14	15	15	15	15	16	16	16
Total Other Income / (Expense), net	0.28	0.84	1.32	1.98	2.74	2.46	3.99	4.38	5.50	1.87
Other Income / (Expense), net	0.08	1.09	0.50	1.28	2.74	3.99	3.36	3.56	5.50	3.32
Income Tax Expense	-1.67	0.73	-1.35	2.18	5.03	2.79	5.62	8.58	7.54	7.13
Basic Earnings per Share	$0.14	$0.04	$0.19	$0.16	$0.17	$0.13	$0.18	$0.18	$0.12	$0.11
Weighted Average Basic Shares Outstanding	92.32M	92.20M	93.83M	94.74M	95.50M	95.02M	96.48M	93.87M	90.07M	91.48M
Diluted Earnings per Share	$0.13	$0.03	$0.18	$0.15	$0.16	$0.13	$0.17	$0.17	$0.11	$0.12
Weighted Average Diluted Shares Outstanding	99.82M	99.96M	100.17M	100.62M	100.88M	100.67M	101.05M	97.84M	93.82M	95.45M
Weighted Average Basic & Diluted Shares Outstanding	92.88M	93.38M	94.41M	95.41M	95.84M	96.50M	95.22M	90.28M	85.15M	85.41M

This table details how cash moves in and out of Progyny's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.68	-4.56	80	-10	21	29	-23	65
Net Cash From Operating Activities	-9.47	2.27	-1.53	36	26	80	189	179
Net Cash From Continuing Operating Activities	-9.42	2.27	-1.53	36	26	80	189	179
Net Income / (Loss) Continuing Operations	-12	-5.12	-8.57	46	66	30	62	54
Consolidated Net Income / (Loss)	-12	0.66	-8.57	46	66	30	62	54
Depreciation Expense	1.56	1.88	2.13	1.91	1.30	1.60	2.28	3.18
Non-Cash Adjustments To Reconcile Net Income	2.91	6.93	25	18	10	115	138	144
Changes in Operating Assets and Liabilities, net	-1.43	-1.42	-20	-31	-51	-66	-14	-22
Net Cash From Investing Activities	-0.61	1.90	-2.76	-40	8.77	-44	-201	196
Net Cash From Continuing Investing Activities	-0.61	-0.58	-2.96	-40	8.77	-44	-201	196
Purchase of Property, Plant & Equipment	-0.61	-0.58	-2.96	-1.04	-2.13	-3.24	-3.64	-5.41
Acquisitions	-	-	-	-	-	0.00	0.00	-5.30
Purchase of Investments	-	0.00	-	-104	-111	-163	-430	-170
Sale and/or Maturity of Investments	-	0.00	-	65	122	123	233	377
Net Cash From Financing Activities	12	-8.74	85	-6.25	-14	-7.86	-11	-310
Net Cash From Continuing Financing Activities	12	-8.74	85	-6.25	-14	-7.86	-11	-310
Repurchase of Common Equity	0.00	-1.21	-3.02	-0.89	-	0.00	0.00	-300
Issuance of Common Equity	0.00	0.00	81	1.24	1.35	1.15	1.28	1.30
Other Financing Activities, net	0.03	0.07	6.60	-6.60	-15	-9.02	-12	-11
Effect of Exchange Rate Changes	-	-	-	-	0.00	0.00	0.00	0.00
Cash Income Taxes Paid	-	-	-	0.00	0.10	0.13	6.18	40

This table details how cash moves in and out of Progyny's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	18	48	35	15	-12	-61	18	-20	-3.48	71
Net Cash From Operating Activities	21	52	21	76	54	38	26	57	45	52
Net Cash From Continuing Operating Activities	21	52	21	76	54	38	26	57	45	52
Net Income / (Loss) Continuing Operations	13	3.41	18	15	16	13	17	16	10	11
Consolidated Net Income / (Loss)	13	3.41	18	15	16	13	17	16	10	11
Depreciation Expense	0.41	0.45	0.54	0.53	0.58	0.63	0.72	0.75	0.84	0.87
Non-Cash Adjustments To Reconcile Net Income	27	33	36	35	38	29	32	34	43	34
Changes in Operating Assets and Liabilities, net	-20	14	-33	25	2.49	-8.38	-24	5.10	-6.36	3.19
Net Cash From Investing Activities	-1.88	-1.17	16	-59	-64	-93	19	86	15	75
Net Cash From Continuing Investing Activities	-1.88	-1.17	16	-59	-64	-93	19	86	15	75
Purchase of Property, Plant & Equipment	-1.24	-0.72	-1.25	-0.76	-1.08	-0.55	-0.85	-0.87	-1.94	-1.75
Sale and/or Maturity of Investments	30	38	41	39	79	74	131	140	29	77
Net Cash From Financing Activities	-1.23	-2.79	-1.85	-1.84	-2.36	-5.03	-27	-163	-63	-56
Net Cash From Continuing Financing Activities	-1.23	-2.79	-1.85	-1.84	-2.36	-5.03	-27	-163	-63	-56
Repurchase of Common Equity	-	-	0.00	-	-	-	-24	-160	-61	-55
Issuance of Common Equity	0.17	0.40	0.29	0.32	0.27	0.39	0.35	0.36	0.21	0.39
Other Financing Activities, net	-1.40	-3.19	-2.14	-2.16	-2.63	-5.42	-4.00	-3.19	-2.11	-1.61
Cash Income Taxes Paid	0.09	-0.01	-0.02	0.72	1.62	3.86	-0.36	18	18	5.58

This table presents Progyny's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	41	150	254	358	543	757	607
Total Current Assets	25	132	190	259	434	640	473
Cash & Equivalents	0.13	80	70	91	120	97	162
Short-Term Investments	-	0.00	39	28	69	274	66
Accounts Receivable	23	47	76	135	240	242	235
Prepaid Expenses	0.89	5.00	5.26	4.56	4.49	27	9.44
Plant, Property, & Equipment, net	0.78	3.08	3.40	5.03	8.37	10	12
Total Noncurrent Assets	16	15	60	94	101	106	122
Goodwill	12	12	12	12	12	12	16
Intangible Assets	3.86	2.38	1.21	0.60	0.10	0.00	1.30
Noncurrent Deferred & Refundable Income Taxes	-	0.00	38	71	78	73	85
Other Noncurrent Operating Assets	0.27	0.65	9.24	11	11	21	20
Total Liabilities & Shareholders' Equity	41	150	254	358	543	757	607
Total Liabilities	30	36	87	106	166	203	185
Total Current Liabilities	30	36	78	99	160	186	169
Accounts Payable	16	19	44	61	109	125	95
Accrued Expenses	9.78	17	34	37	50	61	74
Total Noncurrent Liabilities	0.00	0.00	9.19	7.42	6.48	17	16
Other Noncurrent Operating Liabilities	-	0.00	9.19	7.42	6.48	17	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-95	114	167	252	377	553	422
Total Preferred & Common Equity	-95	114	167	252	377	553	422
Total Common Equity	-95	114	167	252	377	553	422
Common Stock	11	229	236	255	350	462	582
Retained Earnings	-105	-113	-68	-2.42	28	90	144
Treasury Stock	-	-	-	-	-	-1.01	-304
Accumulated Other Comprehensive Income / (Loss)	-	0.00	0.00	-0.09	0.50	2.82	0.04

This table presents Progyny's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	510	650	682	727	794	699	660
Total Current Assets	402	527	561	611	682	582	546
Cash & Equivalents	73	155	171	158	115	95	91
Short-Term Investments	68	53	112	177	257	167	144
Accounts Receivable	258	313	265	269	297	294	281
Prepaid Expenses	2.84	5.95	14	6.95	12	26	30
Plant, Property, & Equipment, net	7.20	8.88	9.50	9.72	10	11	12
Total Noncurrent Assets	101	114	111	106	103	106	102
Goodwill	12	12	12	12	12	16	16
Intangible Assets	0.22	0.00	0.00	0.00	-	1.48	1.45
Noncurrent Deferred & Refundable Income Taxes	78	79	77	72	70	68	64
Other Noncurrent Operating Assets	11	23	22	22	20	21	21
Total Liabilities & Shareholders' Equity	510	650	682	727	794	699	660
Total Liabilities	164	225	212	211	223	242	225
Total Current Liabilities	157	207	194	193	206	225	208
Accounts Payable	104	146	130	132	130	152	130
Accrued Expenses	53	61	64	61	76	74	78
Total Noncurrent Liabilities	6.72	18	18	18	17	17	17
Other Noncurrent Operating Liabilities	6.72	18	18	18	17	17	17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	347	424	469	515	572	456	435
Total Preferred & Common Equity	347	424	469	515	572	456	435
Total Common Equity	347	424	469	515	572	456	435
Common Stock	323	379	409	438	489	520	552
Retained Earnings	25	46	61	77	107	123	134
Treasury Stock	-	-	-	-	-27	-	-251
Accumulated Other Comprehensive Income / (Loss)	0.21	0.72	1.08	1.85	2.75	2.03	0.33

This table displays calculated financial ratios and metrics derived from Progyny's official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	116.94%	117.92%	50.15%	45.17%	57.19%	38.34%	7.22%
EBITDA Growth	0.00%	61.14%	-41.06%	264.37%	218.00%	-21.74%	180.21%	18.37%
EBIT Growth	0.00%	51.45%	-32.88%	200.69%	273.62%	-23.56%	189.23%	17.70%
NOPAT Growth	0.00%	68.63%	380.33%	559.70%	46.75%	-55.79%	88.23%	-19.28%
Net Income Growth	0.00%	105.31%	-1,396.37%	642.18%	41.56%	-53.84%	104.35%	-12.41%
EPS Growth	0.00%	101.69%	-1,125.00%	214.63%	40.43%	-54.55%	106.67%	-8.06%
Operating Cash Flow Growth	0.00%	123.98%	-167.52%	2,460.04%	-28.08%	208.77%	134.86%	-5.14%
Free Cash Flow Firm Growth	0.00%	0.00%	-19.33%	230.25%	-143.86%	-186.20%	327.99%	-46.10%
Invested Capital Growth	0.00%	0.00%	206.74%	70.11%	129.68%	41.74%	-2.84%	6.45%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	11.36%	5.76%	12.39%	5.38%	2.50%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	96.62%	-5.19%	23.80%	24.58%	5.95%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	156.15%	-4.98%	24.92%	25.16%	5.88%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	443.40%	-26.25%	-30.83%	18.97%	-3.89%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	1,455.37%	-26.73%	-27.77%	19.36%	-5.13%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-38.16%	-26.67%	-28.57%	19.23%	-1.72%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-119.05%	49.74%	9.59%	113.29%	-6.84%	8.81%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-745.81%	51.48%	-16.68%	21.74%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	158.42%	20.58%	-8.84%	1.39%	-2.53%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	15.23%	18.44%	19.81%	20.32%	22.40%	21.26%	21.94%	21.71%
EBITDA Margin	-23.91%	-4.28%	-2.77%	3.03%	6.65%	3.31%	6.70%	7.40%
Operating Margin	-22.65%	-3.28%	4.21%	2.42%	6.46%	2.97%	5.71%	5.78%
EBIT Margin	-27.11%	-6.07%	-3.70%	2.48%	6.39%	3.11%	6.49%	7.13%
Profit (Net Income) Margin	-25.63%	0.63%	-3.73%	13.47%	13.14%	3.86%	5.70%	4.66%
Tax Burden Percent	99.94%	-9.59%	100.14%	535.30%	202.77%	124.21%	87.76%	65.31%
Interest Burden Percent	94.58%	107.77%	100.68%	101.41%	101.44%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	-435.30%	-102.77%	-24.21%	12.24%	34.69%
Return on Invested Capital (ROIC)	0.00%	-43.74%	30.15%	97.64%	69.01%	18.12%	29.50%	23.40%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-8,361.04%	68.29%	95.77%	68.84%	17.23%	26.83%	19.97%
Return on Net Nonoperating Assets (RNNOA)	0.00%	55.63%	-43.82%	-64.60%	-37.60%	-8.46%	-16.16%	-12.26%
Return on Equity (ROE)	0.00%	11.89%	-13.67%	33.04%	31.41%	9.66%	13.34%	11.14%
Cash Return on Invested Capital (CROIC)	0.00%	-243.74%	-71.51%	45.73%	-9.66%	-16.42%	32.38%	17.15%
Operating Return on Assets (OROA)	0.00%	-15.48%	-8.86%	4.23%	10.45%	5.43%	10.88%	12.20%
Return on Assets (ROA)	0.00%	1.60%	-8.94%	22.98%	21.49%	6.74%	9.55%	7.97%
Return on Common Equity (ROCE)	0.00%	-101.65%	-2.09%	33.04%	31.41%	9.66%	13.34%	11.14%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-0.69%	-7.50%	27.83%	26.12%	8.05%	11.21%	12.87%
Net Operating Profit after Tax (NOPAT)	-7.70	-2.42	6.77	45	66	29	55	44
NOPAT Margin	-15.86%	-2.29%	2.95%	12.96%	13.10%	3.68%	5.01%	3.77%
Net Nonoperating Expense Percent (NNEP)	0.00%	8,317.30%	-38.14%	1.87%	0.17%	0.89%	2.66%	3.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	7.69%	9.86%	10.44%
Cost of Revenue to Revenue	84.77%	81.56%	80.19%	79.68%	77.60%	78.74%	78.06%	78.29%
SG&A Expenses to Revenue	29.12%	14.80%	10.42%	13.54%	11.91%	12.50%	10.76%	10.45%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	75.77%	21.71%	15.60%	17.89%	15.94%	18.30%	16.22%	15.93%
Earnings before Interest and Taxes (EBIT)	-13	-6.40	-8.50	8.56	32	24	71	83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-12	-4.51	-6.37	10	33	26	73	86
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	20.19	22.00	18.08	7.68	6.44	3.48
Price to Tangible Book Value (P/TBV)	0.00	0.00	23.07	23.87	19.02	7.93	6.58	3.62
Price to Revenue (P/Rev)	2.68	1.23	10.04	10.65	9.10	3.68	3.27	1.26
Price to Earnings (P/E)	0.00	0.00	0.00	79.05	69.23	95.31	57.44	27.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.27%	1.44%	1.05%	1.74%	3.70%
Enterprise Value to Invested Capital (EV/IC)	0.00	21.39	65.71	61.81	33.49	14.41	17.51	6.39
Enterprise Value to Revenue (EV/Rev)	0.00	2.24	9.69	10.33	8.86	3.44	2.93	1.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	340.51	133.25	103.83	43.74	14.37
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	416.35	138.67	110.63	45.16	14.91
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	328.72	79.73	67.61	93.27	58.49	28.17
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	104.03	0.00	98.42	170.29	33.63	16.91	6.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	170.25	0.00	0.00	53.29	38.44
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-0.01	-0.64	-0.67	-0.55	-0.49	-0.60	-0.61
Leverage Ratio	0.00	3.72	1.53	1.44	1.46	1.43	1.40	1.40
Compound Leverage Factor	0.00	4.00	1.54	1.46	1.48	1.43	1.40	1.40
Debt to Total Capital	0.00%	2.22%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.22%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	933.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-836.18%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.06	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-0.03	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.10	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-0.05	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.91	39.33	26.96	27.93	12.73	13.16	8.07
Noncontrolling Interest Sharing Ratio	0.00%	955.20%	84.72%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.81	3.66	2.45	2.62	2.72	3.44	2.80
Quick Ratio	0.00	0.78	3.52	2.38	2.57	2.69	3.30	2.75
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-13	-16	21	-9.18	-26	60	32
Operating Cash Flow to CapEx	-1,548.04%	392.40%	-51.89%	3,491.13%	1,222.97%	2,480.56%	5,181.50%	3,313.69%
Free Cash Flow to Firm to Interest Expense	0.00	-27.09	-277.02	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-12.80	4.57	-26.45	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-13.63	3.41	-77.41	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	2.55	2.40	1.71	1.64	1.75	1.68	1.71
Accounts Receivable Turnover	0.00	4.52	6.53	5.62	4.76	4.20	4.52	4.89
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	135.82	119.04	106.39	118.81	117.47	117.15	103.31
Accounts Payable Turnover	0.00	5.52	10.53	8.74	7.41	7.26	7.24	8.29
Days Sales Outstanding (DSO)	0.00	80.77	55.93	64.95	76.64	86.88	80.80	74.61
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	66.14	34.65	41.77	49.29	50.28	50.41	44.04
Cash Conversion Cycle (CCC)	0.00	14.63	21.28	23.17	27.35	36.61	30.39	30.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	11	34	58	132	188	182	194
Invested Capital Turnover	0.00	19.08	10.22	7.53	5.27	4.92	5.88	6.20
Increase / (Decrease) in Invested Capital	0.00	11	23	24	75	55	-5.33	12
Enterprise Value (EV)	0.00	236	2,227	3,563	4,434	2,704	3,192	1,241
Market Capitalization	130	130	2,307	3,672	4,553	2,893	3,563	1,469
Book Value per Share	$0.00	($17.17)	$1.36	$1.93	$2.78	$4.06	$5.77	$4.96
Tangible Book Value per Share	$0.00	($20.01)	$1.19	$1.78	$2.65	$3.93	$5.65	$4.76
Total Capital	0.00	11	114	167	252	377	553	422
Total Debt	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	0.13	-80	-109	-119	-189	-371	-228
Capital Expenditures (CapEx)	0.61	0.58	2.96	1.04	2.13	3.24	3.64	5.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-5.54	16	3.14	40	85	83	76
Debt-free Net Working Capital (DFNWC)	0.00	-5.41	96	112	160	274	454	304
Net Working Capital (NWC)	0.00	-5.67	96	112	160	274	454	304
Net Nonoperating Expense (NNE)	4.75	-3.08	15	-1.77	-0.19	-1.37	-7.47	-10
Net Nonoperating Obligations (NNO)	0.00	-0.07	-80	-109	-119	-189	-371	-228
Total Depreciation and Amortization (D&A)	1.56	1.88	2.13	1.91	1.30	1.60	2.28	3.18
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-5.26%	6.92%	0.91%	8.05%	10.80%	7.66%	6.52%
Debt-free Net Working Capital to Revenue	0.00%	-5.13%	41.92%	32.60%	31.90%	34.86%	41.75%	26.05%
Net Working Capital to Revenue	0.00%	-5.37%	41.92%	32.60%	31.90%	34.86%	41.75%	26.05%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.65	$0.59
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	95.02M	91.48M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.62	$0.57
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	100.67M	95.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	96.50M	85.41M
Normalized Net Operating Profit after Tax (NOPAT)	-7.70	-2.42	6.77	5.84	23	16	55	44
Normalized NOPAT Margin	-15.86%	-2.29%	2.95%	1.69%	4.52%	2.08%	5.01%	3.77%
Pre Tax Income Margin	-25.64%	-6.54%	-3.73%	2.52%	6.48%	3.11%	6.49%	7.13%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-17.80	-12.87	-146.53	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-10.41	-4.86	116.79	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-18.63	-14.03	-197.50	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-11.24	-6.03	65.83	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	182.30%	-35.24%	1.92%	0.00%	0.00%	0.00%	552.63%

This table displays calculated financial ratios and metrics derived from Progyny's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	67.95%	68.03%	50.04%	43.27%	36.77%	25.95%	7.62%	8.85%	2.04%	10.55%
EBITDA Growth	27.08%	3,033.94%	7,542.86%	83.67%	83.19%	280.58%	40.80%	47.19%	-12.60%	8.41%
EBIT Growth	26.35%	1,013.72%	10,170.78%	85.73%	84.63%	304.78%	41.10%	47.32%	-14.18%	7.40%
NOPAT Growth	-22.84%	2,167.48%	40,122.48%	52.34%	7.21%	320.12%	-14.45%	2.60%	-47.68%	-17.62%
Net Income Growth	-21.34%	-77.40%	255.62%	70.97%	20.34%	295.25%	-4.41%	9.97%	-34.45%	-21.81%
EPS Growth	-23.53%	-80.00%	260.00%	66.67%	23.08%	333.33%	-5.56%	13.33%	-31.25%	-7.69%
Operating Cash Flow Growth	-13.53%	484.42%	286.12%	294.95%	159.32%	-26.90%	22.76%	-25.41%	-17.84%	38.52%
Free Cash Flow Firm Growth	-17.49%	29.84%	72.66%	121.47%	147.90%	131.89%	216.42%	-55.66%	-130.34%	-114.02%
Invested Capital Growth	87.48%	41.74%	24.47%	-0.87%	-12.64%	-2.84%	-7.73%	3.74%	10.74%	6.45%
Revenue Q/Q Growth	5.32%	4.36%	20.56%	8.12%	0.54%	-3.90%	3.01%	9.35%	-5.74%	4.12%
EBITDA Q/Q Growth	26.95%	-58.77%	298.56%	5.84%	26.62%	-14.35%	39.90%	10.65%	-24.82%	6.25%
EBIT Q/Q Growth	27.91%	-61.23%	333.09%	6.14%	27.16%	-15.01%	41.00%	10.82%	-25.93%	6.37%
NOPAT Q/Q Growth	48.05%	-78.89%	497.22%	-18.40%	4.19%	-17.26%	21.62%	-2.14%	-46.87%	30.28%
Net Income Q/Q Growth	50.67%	-74.20%	418.72%	-15.20%	6.05%	-15.27%	25.45%	-2.44%	-36.79%	1.07%
EPS Q/Q Growth	44.44%	-76.92%	500.00%	-16.67%	6.67%	-18.75%	30.77%	0.00%	-35.29%	9.09%
Operating Cash Flow Q/Q Growth	8.56%	146.56%	-59.31%	262.64%	-28.72%	-30.50%	-31.67%	120.32%	-21.48%	17.18%
Free Cash Flow Firm Q/Q Growth	-19.91%	36.83%	49.91%	156.59%	167.47%	-57.94%	82.86%	-78.45%	-283.04%	80.56%
Invested Capital Q/Q Growth	9.13%	-8.84%	15.37%	-13.63%	-3.83%	1.39%	9.56%	-2.89%	2.66%	-2.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	22.40%	20.76%	22.69%	21.71%	22.29%	21.08%	22.44%	22.45%	20.67%	21.26%
EBITDA Margin	5.72%	2.26%	6.21%	6.08%	7.66%	6.83%	8.13%	8.22%	6.56%	6.69%
Operating Margin	5.48%	1.54%	5.81%	5.44%	6.48%	5.11%	6.66%	6.80%	4.35%	5.29%
EBIT Margin	5.52%	2.05%	6.00%	5.89%	7.45%	6.59%	7.87%	7.98%	6.27%	6.40%
Profit (Net Income) Margin	6.43%	1.59%	6.84%	5.37%	5.66%	4.99%	6.08%	5.42%	3.64%	3.53%
Tax Burden Percent	114.49%	82.30%	108.25%	87.32%	75.95%	82.83%	75.05%	65.76%	58.02%	59.64%
Interest Burden Percent	101.78%	94.22%	105.30%	104.29%	100.00%	91.41%	102.89%	103.36%	100.00%	92.42%
Effective Tax Rate	-14.49%	17.70%	-8.25%	12.68%	24.05%	17.17%	24.95%	34.24%	41.98%	40.36%
Return on Invested Capital (ROIC)	27.83%	6.24%	28.12%	24.19%	26.34%	24.92%	26.62%	26.61%	15.15%	19.57%
ROIC Less NNEP Spread (ROIC-NNEP)	27.58%	5.80%	27.21%	23.34%	25.47%	24.19%	25.59%	25.55%	14.04%	19.19%
Return on Net Nonoperating Assets (RNNOA)	-12.33%	-2.85%	-12.12%	-12.11%	-14.08%	-14.57%	-14.89%	-15.03%	-8.44%	-11.79%
Return on Equity (ROE)	15.50%	3.40%	16.00%	12.09%	12.27%	10.35%	11.73%	11.57%	6.72%	7.78%
Cash Return on Invested Capital (CROIC)	-34.31%	-16.42%	-1.10%	24.75%	37.28%	32.38%	33.19%	23.99%	14.00%	17.15%
Operating Return on Assets (OROA)	9.12%	3.58%	9.84%	9.86%	12.45%	11.04%	12.08%	13.09%	10.29%	10.96%
Return on Assets (ROA)	10.63%	2.78%	11.21%	8.98%	9.45%	8.36%	9.33%	8.90%	5.97%	6.04%
Return on Common Equity (ROCE)	15.50%	3.40%	16.00%	12.09%	12.27%	10.35%	11.73%	11.57%	6.72%	7.78%
Return on Equity Simple (ROE_SIMPLE)	12.12%	0.00%	10.15%	10.50%	10.08%	0.00%	10.72%	13.76%	13.17%	0.00%
Net Operating Profit after Tax (NOPAT)	13	2.72	16	13	14	11	14	14	7.23	9.42
NOPAT Margin	6.27%	1.27%	6.29%	4.75%	4.92%	4.23%	5.00%	4.47%	2.52%	3.16%
Net Nonoperating Expense Percent (NNEP)	0.25%	0.45%	0.91%	0.86%	0.87%	0.73%	1.03%	1.06%	1.12%	0.37%
Return On Investment Capital (ROIC_SIMPLE)	-	0.72%	-	-	-	2.07%	-	-	-	2.23%
Cost of Revenue to Revenue	77.60%	79.24%	77.31%	78.29%	77.71%	78.92%	77.56%	77.55%	79.33%	78.74%
SG&A Expenses to Revenue	11.48%	13.16%	11.36%	10.76%	10.51%	10.44%	10.22%	10.25%	10.58%	10.73%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	16.92%	19.22%	16.88%	16.27%	15.82%	15.96%	15.78%	15.65%	16.32%	15.97%
Earnings before Interest and Taxes (EBIT)	11	4.40	16	16	21	18	22	24	18	19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	4.84	16	17	22	18	23	25	19	20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.84	7.68	7.07	7.91	6.30	6.44	6.44	5.97	3.48	3.48
Price to Tangible Book Value (P/TBV)	10.19	7.93	7.27	8.12	6.45	6.58	6.58	6.20	3.62	3.62
Price to Revenue (P/Rev)	4.87	3.68	3.44	3.88	3.14	3.27	3.32	2.40	1.33	1.26
Price to Earnings (P/E)	81.19	95.31	69.65	75.35	62.45	57.44	60.10	43.41	26.42	27.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.23%	1.05%	1.44%	1.33%	1.60%	1.74%	1.66%	2.30%	3.79%	3.70%
Enterprise Value to Invested Capital (EV/IC)	15.89	14.41	12.89	18.35	16.18	17.51	16.57	12.69	6.41	6.39
Enterprise Value to Revenue (EV/Rev)	4.67	3.44	3.20	3.58	2.82	2.93	2.99	2.17	1.12	1.06
Enterprise Value to EBITDA (EV/EBITDA)	155.52	103.83	67.97	70.31	49.68	43.74	43.42	29.23	15.67	14.37
Enterprise Value to EBIT (EV/EBIT)	167.21	110.63	71.05	73.18	51.52	45.16	44.87	30.19	16.25	14.91
Enterprise Value to NOPAT (EV/NOPAT)	78.05	93.27	69.04	76.50	63.44	58.49	63.22	46.72	27.87	28.17
Enterprise Value to Operating Cash Flow (EV/OCF)	86.79	33.63	24.79	20.26	14.36	16.91	17.10	14.13	7.76	6.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	73.81	40.48	53.29	47.90	53.87	48.16	38.44
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.45	-0.49	-0.45	-0.52	-0.55	-0.60	-0.58	-0.59	-0.60	-0.61
Leverage Ratio	1.48	1.43	1.51	1.47	1.43	1.40	1.45	1.49	1.46	1.40
Compound Leverage Factor	1.51	1.35	1.59	1.53	1.43	1.28	1.49	1.54	1.46	1.29
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.60	12.61	10.10	12.77	11.58	12.93	12.31	9.34	6.75	7.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.56	2.72	2.55	2.89	3.16	3.44	3.31	2.58	2.62	2.80
Quick Ratio	2.54	2.69	2.52	2.82	3.12	3.30	3.25	2.47	2.48	2.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-83	-53	-26	15	40	17	31	6.60	-12	-2.35
Operating Cash Flow to CapEx	1,685.00%	7,145.22%	1,675.54%	10,014.76%	5,012.21%	6,809.95%	3,027.29%	6,546.65%	2,296.96%	2,979.10%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.65	1.75	1.64	1.67	1.67	1.68	1.54	1.64	1.64	1.71
Accounts Receivable Turnover	3.56	4.20	3.41	3.87	3.92	4.52	3.63	4.06	4.14	4.89
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	117.64	117.47	118.71	121.40	122.12	117.15	115.95	112.55	105.22	103.31
Accounts Payable Turnover	6.92	7.26	5.91	6.71	6.83	7.24	6.28	6.26	6.80	8.29
Days Sales Outstanding (DSO)	102.50	86.88	106.89	94.32	93.07	80.80	100.52	90.00	88.06	74.61
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	52.74	50.28	61.80	54.39	53.44	50.41	58.14	58.28	53.71	44.04
Cash Conversion Cycle (CCC)	49.75	36.61	45.09	39.93	39.63	30.39	42.38	31.72	34.35	30.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	206	188	217	187	180	182	200	194	199	194
Invested Capital Turnover	4.44	4.92	4.47	5.10	5.36	5.88	5.32	5.95	6.01	6.20
Increase / (Decrease) in Invested Capital	96	55	43	-1.64	-26	-5.33	-17	7.00	19	12
Enterprise Value (EV)	3,272	2,704	2,791	3,431	2,910	3,192	3,310	2,462	1,277	1,241
Market Capitalization	3,413	2,893	2,999	3,714	3,246	3,563	3,681	2,724	1,513	1,469
Book Value per Share	$3.77	$4.06	$4.55	$4.97	$5.40	$5.77	$5.92	$4.79	$4.82	$4.96
Tangible Book Value per Share	$3.64	$3.93	$4.42	$4.85	$5.28	$5.65	$5.80	$4.61	$4.63	$4.76
Total Capital	347	377	424	469	515	553	572	456	435	422
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-141	-189	-208	-282	-336	-371	-372	-262	-236	-228
Capital Expenditures (CapEx)	1.24	0.72	1.25	0.76	1.08	0.55	0.85	0.87	1.94	1.75
Debt-free, Cash-free Net Working Capital (DFCFNWC)	104	85	112	85	82	83	104	95	102	76
Debt-free Net Working Capital (DFNWC)	245	274	320	367	418	454	476	357	338	304
Net Working Capital (NWC)	245	274	320	367	418	454	476	357	338	304
Net Nonoperating Expense (NNE)	-0.33	-0.69	-1.43	-1.73	-2.08	-2.04	-3.00	-2.88	-3.19	-1.12
Net Nonoperating Obligations (NNO)	-141	-189	-208	-282	-336	-371	-372	-262	-236	-228
Total Depreciation and Amortization (D&A)	0.41	0.45	0.54	0.53	0.58	0.63	0.72	0.75	0.84	0.87
Debt-free, Cash-free Net Working Capital to Revenue	14.85%	10.80%	12.87%	8.85%	7.97%	7.66%	9.36%	8.36%	8.97%	6.52%
Debt-free Net Working Capital to Revenue	34.99%	34.86%	36.68%	38.35%	40.45%	41.75%	42.91%	31.50%	29.67%	26.05%
Net Working Capital to Revenue	34.99%	34.86%	36.68%	38.35%	40.45%	41.75%	42.91%	31.50%	29.67%	26.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	$0.04	$0.19	$160.00	$0.17	$0.13	$0.18	$0.18	$0.12	$0.11
Adjusted Weighted Average Basic Shares Outstanding	92.32M	92.20M	93.83M	94.74K	95.50M	95.02M	96.48M	93.87M	90.07M	91.48M
Adjusted Diluted Earnings per Share	$0.13	$0.03	$0.18	$150.00	$0.16	$0.13	$0.17	$0.17	$0.11	$0.12
Adjusted Weighted Average Diluted Shares Outstanding	99.82M	99.96M	100.17M	100.62K	100.88M	100.67M	101.05M	97.84M	93.82M	95.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	92.88M	93.38M	94.41M	95.41M	95.84M	96.50M	95.22M	90.28M	85.15M	85.41M
Normalized Net Operating Profit after Tax (NOPAT)	7.88	2.72	11	13	14	11	14	14	7.23	9.42
Normalized NOPAT Margin	3.84%	1.27%	4.07%	4.75%	4.92%	4.23%	5.00%	4.47%	2.52%	3.16%
Pre Tax Income Margin	5.62%	1.93%	6.32%	6.14%	7.45%	6.02%	8.10%	8.24%	6.27%	5.92%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	552.63%

Key Financial Trends

Progyny (NASDAQ:PGNY) has delivered consistent top-line growth over the past four years, driven by strong demand for its fertility benefits platform. The company remains debt-free, generates healthy operating cash flow, and continues to invest in its business while returning capital to shareholders. However, net income and margins peaked in 2023 and have softened in Q4 2024, and valuation multiples remain elevated compared with historical averages.

Steady revenue growth: Total revenue rose from $214.3 million in Q4 2022 to $298.4 million in Q4 2024, a compound annual growth rate of over 15%.
Robust operating cash flow: Net cash from operating activities recovered to $52.2 million in Q4 2024, up 17% sequentially and back above pre-2023 levels.
Debt-free balance sheet: Net debt stands at –$228 million (net cash), supporting financial flexibility for growth investments and buybacks.
Improving operating income: Q4 operating income increased from $3.3 million in 2022 to $15.8 million in 2024, reflecting scalable economics.
Valuation remains rich: Shares trade at ~27× trailing P/E and ~14× EV/EBITDA, near historical highs for the sector.
Share repurchases: The company spent $55 million on buybacks in Q4 2024, reflecting capital return priority but reducing cash.
Investment portfolio shifts: Q4 2024 saw $76.9 million of investments sold, boosting cash but reflecting portfolio management.
Net income contraction: Q4 2024 net income fell 22% year-over-year to $10.5 million, pressuring EPS ($0.12 versus $0.13 in Q4 2023).
Margin compression: Gross margin edged up to 21.3% in Q4 2024 but remains under pressure from cost of revenue, compared with peak margins in 2021–2022.
Slowing growth rate: Revenue growth decelerated from 26% in Q4 2023 to 10.6% in Q4 2024, signaling potential saturation risks.

06/24/25 07:55 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Progyny's Financials

When does Progyny's financial year end?

According to the most recent income statement we have on file, Progyny's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Progyny's net income changed over the last 7 years?

Progyny's net income appears to be on an upward trend, with a most recent value of $54.34 million in 2024, falling from -$12.45 million in 2017. The previous period was $62.04 million in 2023. Check out Progyny's forecast to explore projected trends and price targets.

What is Progyny's operating income?

Progyny's total operating income in 2024 was $67.46 million, based on the following breakdown:

Total Gross Profit: $253.36 million
Total Operating Expenses: $185.91 million

How has Progyny's revenue changed over the last 7 years?

Over the last 7 years, Progyny's total revenue changed from $48.58 million in 2017 to $1.17 billion in 2024, a change of 2,302.5%.

How much debt does Progyny have?

Progyny's total liabilities were at $185.04 million at the end of 2024, a 8.9% decrease from 2023, and a 512.7% increase since 2018.

How much cash does Progyny have?

In the past 6 years, Progyny's cash and equivalents has ranged from $127 thousand in 2018 to $162.31 million in 2024, and is currently $162.31 million as of their latest financial filing in 2024.

How has Progyny's book value per share changed over the last 7 years?

Over the last 7 years, Progyny's book value per share changed from 0.00 in 2017 to 4.96 in 2024, a change of 495.7%.

Related Companies

This page (NASDAQ:PGNY) was last updated on 6/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Financials

Key Financial Trends

Frequently Asked Questions About Progyny's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Financials

Annual Income Statements for Progyny

Quarterly Income Statements for Progyny

Annual Cash Flow Statements for Progyny

Quarterly Cash Flow Statements for Progyny

Annual Balance Sheets for Progyny

Quarterly Balance Sheets for Progyny

Annual Metrics And Ratios for Progyny

Quarterly Metrics And Ratios for Progyny

Key Financial Trends

Frequently Asked Questions About Progyny's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools